132 related articles for article (PubMed ID: 36605578)
1. Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer.
Chen Y; Zhu S; Fu J; Lin J; Sun Y; Lv G; Xie M; Xu T; Qiu L
J Pharm Anal; 2022 Dec; 12(6):869-878. PubMed ID: 36605578
[TBL] [Abstract][Full Text] [Related]
2. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET imaging of
Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
[TBL] [Abstract][Full Text] [Related]
4. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
5. Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [
Liu Q; Wang X; Yang Y; Wang C; Zou J; Lin J; Qiu L
Quant Imaging Med Surg; 2022 Jun; 12(6):3300-3313. PubMed ID: 35655844
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
Yang Y; Wang C; Wang Y; Sun Y; Huang X; Huang M; Xu H; Fan H; Chen D; Zhao F
EJNMMI Res; 2021 Oct; 11(1):113. PubMed ID: 34718889
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
[TBL] [Abstract][Full Text] [Related]
8. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
9. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J
Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
11. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of a Small-Molecule PET Agent for Imaging PD-L1 Expression.
Xu L; Zhang L; Liang B; Zhu S; Lv G; Qiu L; Lin J
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259361
[TBL] [Abstract][Full Text] [Related]
13. Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
Yang H; Zeng X; Liu J; Wen X; Liu H; Liang Y; Wang X; Fang J; Zhang Q; Li J; Zhang X; Guo Z
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1582-1592. PubMed ID: 38246910
[TBL] [Abstract][Full Text] [Related]
14. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
15. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
16. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
[TBL] [Abstract][Full Text] [Related]
17. A novel
Ge S; Zhang B; Li J; Shi J; Jia T; Wang Y; Chen Z; Sang S; Deng S
Bioorg Chem; 2023 Nov; 140():106785. PubMed ID: 37639759
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
19. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
20. Development and Preclinical Evaluation of [
Huang Y; Li C; Li Z; Wang Q; Huang S; Liu Q; Liang Y
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
